Home Investment Analysts' Downgrades for November, 28th (ACT, AUE,...
 

Keywords :   


Investment Analysts' Downgrades for November, 28th (ACT, AUE,...

2013-11-29 11:35:04| Biotech - Topix.net

They currently have $172.00 price target on the stock. Zacks' analyst wrote, "Actavis' third quarter EPS of $2.09 was a penny short of the Zacks Consensus Estimate but up 55% y/y.

Tags: november act investment 28th

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05M&S website and app hit by technical issue
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
18.05This Week in Agribusiness, May 18, 2024
18.05This Week in Agribusiness, May 18, 2024
More »